LAL

RxSight, Inc. Expands Commercial Leadership with Addition of Steve Everly as Vice-President of U.S. Sales

Retrieved on: 
Tuesday, August 17, 2021
Terminology, Adoption, Johnson & Johnson, GLOBE, IOL, Visual acuity, NASDAQ, Abbott Laboratories, Patient, Laboratory, Johnson & Johnson Vision, LAL, Technology, Medicine, Telescopic sight, Pharmaceutical industry

Sales.

Key Points: 
  • Sales.
  • In this new position, Mr. Everly will lead the continued development and expansion of the companys sales organization.
  • Most recently, Mr. Everly served as Johnson & Johnson Visions Area Vice President, Surgical Sales Western U.S., responsible for all aspects of Cataract, Refractive and Ocular Surface product sales.
  • Prior to that Mr. Everly spent nine years in roles of increasing responsibility with Abbott Laboratories ultimately becoming Director, US Refractive Sales and nine years in commercial roles at Advanced Medical Optics, Inc.

RxSight Announces Appointments to its Board of Directors

Retrieved on: 
Wednesday, August 11, 2021
Bausch, Visual acuity, Rutgers University, Medtronic, Company, Patient, MBA, Accounting, Technology, Forward-looking statement, GRACE, Senior, IntraLase, Community Exchange System, Spine, Providence College, Financial system, LAL, Terminology, General manager, Pace University, BS, Nasdaq, Board, University, Leadership, Acquisition, Board of directors, IOL, GLOBE, Bausch & Lomb, Growth, Small Business Saturday, Management

The three appointments, including Robert (Bob) Palmisano, Robert Warner and Julie Andrews, joined directors J. Andy Corley, William J.

Key Points: 
  • The three appointments, including Robert (Bob) Palmisano, Robert Warner and Julie Andrews, joined directors J. Andy Corley, William J.
  • Concurrent with the new appointments, the Company announced the resignations of four long-serving board members Bruce Robertson, Ph.D., Daniel Schwartz, M.D., Christopher Cox, and Rick Wolfen.
  • We are excited to welcome Bob, Robert and Julie to the RxSight Board of Directors as we move forward as a public company focused on improving patient vision after cataract surgery.
  • Their shared values and collective expertise across commercial operations, finance and strategy will play a crucial guiding role in the next phase of growth for RxSight, said J. Andy Corley, Chair of the Board of Directors.